DERM Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -31% compared to Journey Medical's net margin of -80.55%. Journey Medical's return on equity of -54.07% beat Fortress Biotech's return on equity of --.

Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 43.81%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 440.54%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.764, suggesting its more volatile than the S&P 500 by 76.434%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Journey Medical quarterly revenues are $13.1M, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Journey Medical's net income of -$4.1M is higher than Fortress Biotech's net income of -$10.6M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.55x versus 0.72x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -31% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -54.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 43.81%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Journey Medical has higher upside potential than NovaBay Pharmaceuticals, analysts believe Journey Medical is more attractive than NovaBay Pharmaceuticals.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $13.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of -$4.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.55x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -31% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -54.07% beat Oragenics's return on equity of --.

Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 43.81%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 588.14%. Given that Oragenics has higher upside potential than Journey Medical, analysts believe Oragenics is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $13.1M, which are larger than Oragenics quarterly revenues of --. Journey Medical's net income of -$4.1M is lower than Oragenics's net income of -$2.2M. Notably, Journey Medical's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.55x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -31% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -54.07% beat Theriva Biologics's return on equity of --.

Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 43.81%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1359.25%. Given that Theriva Biologics has higher upside potential than Journey Medical, analysts believe Theriva Biologics is more attractive than Journey Medical.

Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Journey Medical quarterly revenues are $13.1M, which are larger than Theriva Biologics quarterly revenues of --. Journey Medical's net income of -$4.1M is higher than Theriva Biologics's net income of -$4.3M. Notably, Journey Medical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.55x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.